Clinical Trial Update: OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (OTI-010) evaluating prophylaxis against graft-versus-host disease in patients undergoing donor peripheral blood stem cell transplantat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• OTI-010

Snippet

Sponsor: Mesoblast International Sàrl | Conditions: Graft Versus Host Disease, Leukemia | Phase 2 | Status: WITHDRAWN